Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
multi-characteristic opsin
technology4 mentionslast seen Nov 5, 2026
Proprietary genetically engineered synthetic opsin technology enabling optimized performance with high light sensitivity and fast kinetics.
Relationships 4
- MOGENRYdepends onmulti-characteristic opsin99% confidence4 sources
- Samarendra Mohantyauthoredmulti-characteristic opsin99% confidence2 sources
- Nanoscope Therapeuticsdevelopsmulti-characteristic opsin99% confidence2 sources
- multi-characteristic opsinapplies togeographic atrophy treatment96% confidence2 sources
Relationship
MOGENRYdepends onmulti-characteristic opsin
99% confidence4 supporting mentions
Either name opens that entity’s relationships.
Sources 4
- newsPR NewswireNov 5, 2026Nanoscope Therapeutics Appoints Ophthalmology and Rare Disease Regulatory Leader Damon Daulerio as Executive Director of Regulatory Affairs
MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope's MCO platform
- newsPR NewswireOct 29, 2026Nanoscope Therapeutics to Participate in Advanced Therapies USA 2026 in Boston
MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope's MCO platform
- newsPR NewswireOct 14, 2026Nanoscope Therapeutics Appoints Gene Therapy Operations Leader Troy Short as Senior Vice President, Manufacturing and Supply Chain
MOGENRY is an investigational optogenetic gene therapy built on Nanoscope's MCO platform
- newsPR NewswireSep 29, 2026Nanoscope Therapeutics to Present at Meeting on the Mesa 2026
MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope's MCO platform